Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02269 WUXI BIO
RTNominal down12.700 -0.680 (-5.082%)
Research Report

23/12/2020 17:43

{I-bank focus}Credit Suisse lifts Wuxi Bio (02269) to HK$107

[ET Net News Agency, 23 December 2020] Credit Suisse raised its target price for Wuxi
Biologics (02269) to HK$107 from HK$86.67 given potentially improved CRO (contract
research organization) trend in China, and maintained its "outperform" rating.
Wuxi Bio has entered into an Asset Purchase Agreement with Bayer. Wuxi Bio will purchase
Bayer's biologics DS (drug substance) manufacturing plant (MFG19) in Germany for EUR150mn.
Together with the drug product facility in Germany (DP7) purchased from Bayer in April,
the research house believes these two facilities showcase WuXi Bio's determination on
global expansion. The two plants are expected to be ready for production.
Credit Suisse thinks the recent stock strength potentially comes from improved
sentiments over NRDL (National Reimbursement Drug List) negotiation, which boosted
biotech/pharma stock performance in the last two weeks.
Credit Suisse revised its FY2020/21/22 EPS forecasts by (1.3%)/5.3%/4.6% due to revised
analyst estimates on near-term earnings. (KL)

Remark: Real time quote last updated: 23/09/2024 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.